MedTrace Logo

An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

NCT07724132 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2026-07-23

No results posted yet for this study

Summary

A multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease in a population representative of people with Alzheimer's disease in the UK.

Conditions

  • Alzheimer's Disease (AD)
  • Mild Cognitive Impairment Due to Alzheimer's Disease
  • Alzheimer Disease Dementia

Interventions

DRUG

Placebo

Oral capsule matching active treatments

DRUG

Atomoxetine

Atomoxetine (Oral, up to 100 mg/day)

DRUG

Metformin 1000 mg Oral Tablet

Metformin IR Oral, up to 2000 mg/day

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Imperial College London

    collaborator OTHER

  • UK Dementia Research Institute Ltd

    collaborator UNKNOWN

  • Alzheimers Research UK

    collaborator UNKNOWN

  • University College, London

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-24
Primary Completion
2031-03-31
Completion
2031-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07724132 on ClinicalTrials.gov